Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.

@article{Speicher1991ResistanceTT,
  title={Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.},
  author={Lisa A Speicher and V. R. Sheridan and Andrew K. Godwin and Kenneth D. Tew},
  journal={British Journal of Cancer},
  year={1991},
  volume={64},
  pages={267 - 273}
}
Following EMS mutagenesis, three estramustine (EM) resistant DU 145 human prostatic carcinoma cell lines were clonally selected by exposure to incrementally increasing concentrations of the drug. Although only low levels of resistance (approximately 3-fold) were attainable, this resistance was stable in the absence of continuous drug exposure. These EM-resistant clones (EMR 4,9,12) did not exhibit cross resistance to vinblastine, taxol, or adriamycin, and had collateral sensitivity to… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 51 references

The effects of estramustine on mitotic progression in DU 145 human prostatic carcinoma cells

  • M. SHIODA, H. MUROFUSHI, K. MURAKAMI-MUROFUSHI, H. SA-KAI
  • Eur . J . Cell Biol
  • 1991

A time study on the uptake of estramustine into prostatic tumor 1013 L cells in vitro

  • R. KUSS, S. KHORY, F. RICHARD, F. FOURCADE, P. FRANTZ, J. P. CAPELLE
  • 1989

Anti - invasive activity of estramustine on malignant MO 4 cells and on DU 145 human prostate carcinoma cells in vitro

  • A. ONEFELT
  • Cancer Res .
  • 1988

Broad phase II study of the combination of two microtubule inhibitors: estramustine and vinblastine

  • S.I.P. BELLE, D. SCHALLER, DEWASCH, G. STORREL
  • Proc. Amer. Soc. Clin. Oncol.,
  • 1988
1 Excerpt

Similar Papers

Loading similar papers…